Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Research & Development (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Research & Development for 8 consecutive years, with $58.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 21.05% year-over-year to $58.4 million, compared with a TTM value of $238.3 million through Sep 2025, up 41.94%, and an annual FY2024 reading of $173.0 million, up 10.52% over the prior year.
  • Research & Development was $58.4 million for Q3 2025 at Bicycle Therapeutics, down from $71.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $71.0 million in Q2 2025 and bottomed at $9.7 million in Q1 2021.
  • Average Research & Development over 5 years is $33.9 million, with a median of $34.9 million recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 125.5% in 2023, then increased 0.85% in 2024.
  • Year by year, Research & Development stood at $13.0 million in 2021, then soared by 90.79% to $24.7 million in 2022, then surged by 80.82% to $44.7 million in 2023, then grew by 11.37% to $49.8 million in 2024, then rose by 17.37% to $58.4 million in 2025.
  • Business Quant data shows Research & Development for BCYC at $58.4 million in Q3 2025, $71.0 million in Q2 2025, and $59.1 million in Q1 2025.